OrsoBio, a biotechnology startup developing drugs for obesity, said Tuesday it raised $60 million in a Series A financing round.
The company is developing several treatments for metabolic conditions like obesity and diabetes. Unlike the GLP-1 drugs now popular thanks to the success of Ozempic, Wegovy and Mounjaro, its experimental candidates are aimed at other drug targets.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,